Zepzelca (lurbinectedin) / PharmaMar, Jazz 
Welcome,         Profile    Billing    Logout  
 26 Diseases   31 Trials   31 Trials   1838 News 


12345678910111213...1718»
  • ||||||||||  Review, Journal:  Emerging treatments for sarcoma: from 2024 onward. (Pubmed Central) -  Jan 28, 2025   
    While these strategies have demonstrated some success, the overall improvements in survival have often been modest, irrespective of the therapeutic modality. This underscores critical concerns regarding the true cost-benefit balance and the potential for adverse effects, particularly when evaluated over extended follow-up periods.
  • ||||||||||  temozolomide / Generic mfg.
    Biomarker, Trial initiation date:  Biomarker Directed Trial of Temozolomide and PARP Inhibition in Relapsed SCLC (clinicaltrials.gov) -  Jan 28, 2025   
    P2,  N=152, Not yet recruiting, 
    This underscores critical concerns regarding the true cost-benefit balance and the potential for adverse effects, particularly when evaluated over extended follow-up periods. Initiation date: Jan 2025 --> Jun 2025
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca, Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Enrollment change, Trial completion date, Trial primary completion date:  Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer (clinicaltrials.gov) -  Jan 4, 2025   
    P2,  N=46, Recruiting, 
    Recruiting --> Active, not recruiting N=106 --> 46 | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2024 --> Nov 2025
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Journal:  Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. (Pubmed Central) -  Dec 18, 2024   
    Interestingly, our study shows that lurbinectedin treatment upregulates MHC-I/II genes and CD8 in SCLC clinical samples. We provide mechanistic insights into the effect of lurbinectedin on STING-mediated multimodal immune activation and demonstrate that lurbinectedin treatment represents a promising therapeutic strategy to potentiate the efficacy of immunotherapy in SCLC.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Journal, Combination therapy:  Unveiling the Mechanism of Lurbinectedin's Action and Its Potential in Combination Therapies in Small Cell Lung Cancer. (Pubmed Central) -  Dec 5, 2024   
    Understanding the mechanism of action (MoA) has facilitated the rational combination of lurbinectedin and anticancer therapies with complementary modes of action, in order to obtain synergistic effects that could potentially lead to improved efficacy. This review evaluates the MoA for lurbinectedin and provides an overview of the therapeutic landscape with regards to lurbinectedin combination therapies for the treatment of SCLC based on data from preclinical and clinical studies.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Enrollment change, Trial withdrawal, Metastases:  Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas (clinicaltrials.gov) -  Nov 18, 2024   
    P1/2,  N=0, Withdrawn, 
    This review evaluates the MoA for lurbinectedin and provides an overview of the therapeutic landscape with regards to lurbinectedin combination therapies for the treatment of SCLC based on data from preclinical and clinical studies. N=70 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Review, Journal, IO biomarker:  Lost at SCLC: a review of potential platinum sensitizers. (Pubmed Central) -  Nov 13, 2024   
    By extension, lost at SCLC references the current confusion about how to circumvent the chemoresistance, particularly platinum resistance, which so plagues the treatment of extensive-stage small cell lung cancer (ES-SCLC) that in 2012 the US National Cancer Institute (NCI) designated it a "recalcitrant cancer." Over a decade later, despite the approval of immune checkpoint inhibitors and the conditional approval of lurbinectedin, the prognosis for ES-SCLC, and especially platinum-resistant ES-SCLC, has scarcely improved. The focus of this review, which briefly summarizes current treatment options for ES-SCLC, is on five clinical-stage therapies with the potential to successfully reverse the platinum resistance that is perhaps the biggest obstacle to better clinical outcomes.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Trial completion date, Trial initiation date, Trial primary completion date, Metastases:  Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas (clinicaltrials.gov) -  Sep 19, 2024   
    P1/2,  N=70, Not yet recruiting, 
    Active, not recruiting --> Recruiting Trial completion date: Jul 2027 --> Oct 2027 | Initiation date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jan 2026 --> May 2026
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Trial completion date:  LUPER: Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. (clinicaltrials.gov) -  Aug 19, 2024   
    P1/2,  N=28, Active, not recruiting, 
    All other abstracts will be released on the day of presentation. Trial completion date: Feb 2024 --> Mar 2025
  • ||||||||||  temozolomide / Generic mfg.
    Review, Journal:  Challenges and future perspectives for the use of temozolomide in the treatment of SCLC. (Pubmed Central) -  Aug 17, 2024   
    Several studies have revealed the synergistic activity of temozolomide with poly-ADP-ribose polymerase (PARP) inhibitors, that prevent repair of TMZ-induced DNA damage. This review focuses on the rationale for the use of TMZ in ES-SCLC and provides an overview of the main trials that have evaluated and are currently investigating its role, both as a single-agent and in combinations, in relapse or refractory disease.
  • ||||||||||  Calsed (amrubicin) / BMS, Nippon Kayaku, Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Chemotherapy Sensitivity for Recurrent Small-Cell Lung Cancer Based on Chemotherapy-Free Interval and Treatment Regimens (Exhibit Hall) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2228;    
    The concept of sensitive relapse was established before the advent of amrubicin (available in Japan) and lurbinectedin (recommended in ESMO and NCCN guidelines), which are effective for recurrent SCLC...Thirty-four were treated by platinum-doublet re-challenge, and 29 received monotherapy of amrubicin, topotecan, or irinotecan...It is still unclear whether the response of second-line chemotherapy following ICI is elevated compared to conventional chemotherapy. Further investigation is needed.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Modulation of EMT Increases the Activity of Lurbinectedin in Small Cell Lung Cancer (Exhibit Hall) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1490;    
    Further investigation is needed. Their sensitivity to cisplatin and etoposide (chemotherapeutic drugs), as well as lurbinectedin alone and combination with capmatinib (MET inhibitor), was tested using the Cell Titer-Glo
  • ||||||||||  ABBV-706 / AbbVie, Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Prevalence and Prognostic Impact of SEZ6 Expression in a Real-World Cohort of Patients with Small-Cell Lung Cancer (Exhibit Hall) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1197;    
    P1
    Although the sample size was small and the study was limited to a single site, these data support SEZ6 as a potential ADC-targetable biomarker in SCLC. This real-world SCLC cohort could also be used as a borrowed control for the phase 1 single-arm study being conducted in patients with SCLC treated with ABBV-706 to help identify novel predictive biomarkers and interpret the outcomes from the study.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Teriflunomide in Vitro or Leflunomide in Vivo Treatment Increases the Efficacy of Lurbinectedin in SCLC (30A) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1106;    
    Conclusions : Collectively, our data suggest combinations of Lurbinectedin with Teriflunomide or Leflunomide are a potential therapeutic approach to suppress SCLC progression. These novel results pave the way for clinical trials in the future to validate these treatment strategies in patients with SCLC.
  • ||||||||||  Cosela (trilaciclib) / G1 Therap, Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Trial completion date, Trial primary completion date:  Study of Trilaciclib and Lurbinectidin (clinicaltrials.gov) -  Jun 27, 2024   
    P2,  N=30, Recruiting, 
    This real-world national experience of lurbinectedin post-platinum chemotherapy and immunotherapy for individuals with SCLC was similar to that reported in clinical trials. Trial completion date: Jul 2026 --> Dec 2027 | Trial primary completion date: Jul 2024 --> Dec 2025
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Journal, Tumor mutational burden, PD(L)-1 Biomarker:  Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy. (Pubmed Central) -  Jun 26, 2024   
    A repeat biopsy following the development of lurbinectedin resistance showed a new actionable ERBB2 alteration without significant change in the tumor mutation burden (six mutations/Mb). The present report suggests that lurbinectedin may be active and should be further explored in SCBC harboring TP53 mutations and amplifications in E2F3 and MYC family complexes.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Journal:  Evolution of a Synthetic Strategy toward the Syntheses of Bis-tetrahydroisoquinoline Alkaloids. (Pubmed Central) -  Jun 14, 2024   
    ConspectusThe bis-tetrahydroisoquinoline (bis-THIQ) natural products represent a medicinally important class of isoquinoline alkaloids that exhibit broad biological activities with particularly potent antitumor properties, as exemplified by the two U.S. FDA approved molecules trabectidin and lurbinectedin...Finally, we include our unsuccessful late-stage oxygenation attempts prior to the discovery of the Pd-catalyzed C-O cross-coupling reaction. With this full disclosure of the chemistry developed for the syntheses of bis-THIQs, we hope our orthogonal synthetic tactics will provide useful information and serve as an inspiration for the future development of bis-THIQ pharmaceuticals.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients (clinicaltrials.gov) -  Jun 9, 2024   
    P1,  N=32, Completed, 
    With this full disclosure of the chemistry developed for the syntheses of bis-THIQs, we hope our orthogonal synthetic tactics will provide useful information and serve as an inspiration for the future development of bis-THIQ pharmaceuticals. Recruiting --> Completed | Trial completion date: Dec 2024 --> Nov 2023 | Trial primary completion date: Dec 2024 --> Nov 2023
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca, Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  LURBIMUNE: Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer (clinicaltrials.gov) -  Jun 4, 2024   
    P2,  N=0, Withdrawn, 
    Our findings show that quercetin/lurbinectedin-loaded GO NPs may be a promising lung cancer treatment, opening new avenues for targeted and effective therapies. N=82 --> 0 | Trial completion date: Apr 2026 --> May 2024 | Recruiting --> Withdrawn | Trial primary completion date: Oct 2024 --> May 2024